GLP-1 Drugs and the Heart: What the Evidence Actually Shows A Class of Medicines That Has Outgrown Its Original Purpose GLP-1 receptor agonists were developed to manage blood glucose in type 2 diabetes
The growing body of clinical evidence supporting the long-term efficacy and safety of agents such as semaglutide and tirzepatide has strengthened physician confidence and expanded reimbursement coverage in key markets Moreover, the rising interest from younger demographics, increased public awareness through social media, and celebrity endorsements are normalizing the use of obesity drugs, further accelerating consumer demand
Because of the intended therapeutic use, it is of substantial importance that side effects, such as nausea, be minimized
Fall risk assessment should be included in the monitoring protocol, as rapid weight loss can affect balance and bone density
Sculptra needs at least three sessions, 4-6 weeks apart